Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24016

Title: A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis
Authors: Geusens, Piet
Pavelka, Karel
Rovensky, Jozef
Vanhoof, Johan
Demeester, Nathalie
Calomme, Mario
Vanden Berghe, Dirk
Issue Date: 2017
Citation: BMC MUSCULOSKELETAL DISORDERS, 18, p. 1-12 (Art N° 2)
Abstract: Background: The aim of this study was to assess the efficacy of choline-stabilized orthosilicic acid (ch-OSA) in patients with symptomatic knee osteoarthritis (OA). Methods: In a multicenter, double-blind, placebo-controlled study, 211 patients with knee OA (Kellgren and Lawrence grade II or III) and moderate to moderately severe pain were randomly allocated to ch-OSA or placebo for 12 weeks. The primary outcome was the change in the WOMAC pain subscale from baseline to week 12. Secondary outcomes were changes from baseline to week 12 in WOMAC total, WOMAC stiffness, WOMAC physical function, Subject Global Assessment and levels of cartilage degradation biomarkers C-terminal telopeptide of collagen type II (CTX-II) and cartilage oligomeric matrix protein (COMP). Pre-specified subgroup analyses included the effect of gender. Results: A total of 166 (120 women, 46 men) patients were included in the analysis (87 and 79 in the ch-OSA and placebo group, respectively). In the total study population, no differences were observed between the two treatment groups for the different outcomes but significant treatment x gender interactions were found. In men taking ch-OSA, a significant improvement in WOMAC total, WOMAC stiffness and WOMAC physical function as well as a lower increase in biomarker levels of cartilage degradation was observed, but not in women. The change in WOMAC pain showed a similar positive trend in men taking ch-OSA. Conclusion: After 12 weeks of treatment, no effect was found of ch-OSA in the total study population on clinical parameters and biomarkers, but a gender interaction was observed. In men, ch-OSA was found effective in reducing symptoms of knee OA, which was associated with a slight but significant reduction of biomarkers that are related to cartilage degradation.
Notes: [Geusens, Piet] Hasselt Univ, Biomed Res Inst BIOMED, Diepenbeek, Belgium. [Geusens, Piet] Maastricht UMC, Rheumatol, Maastricht, Netherlands. [Geusens, Piet; Vanhoof, Johan] ReumaClinic, Bretheistr 149, B-3600 Genk, Belgium. [Pavelka, Karel] Inst Rheumatol, Prague, Czech Republic. [Rovensky, Jozef] Nabrezie I Krasku 4782-4, Piestany, Slovakia. [Demeester, Nathalie; Calomme, Mario] Bio Minerals NV, Res & Dev, Destelbergen, Belgium. [Vanden Berghe, Dirk] Univ Antwerp, Dept Pharmaceut Sci, Antwerp, Belgium.
URI: http://hdl.handle.net/1942/24016
DOI: 10.1186/s12891-016-1370-7
ISI #: 000395187700001
ISSN: 1471-2474
Category: A1
Type: Journal Contribution
Validation: ecoom, 2018
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version791.96 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.